Jae Park, MD, Memorial Sloan Kettering Cancer Center

ASH 2021: Updates in the Chronic Lymphocytic Leukemia Treatment Landscape

ByMatthew S. Davids, MD, MMSc, Dana-Farber Cancer Institute,Jae Park, MD, Memorial Sloan Kettering Cancer Center,Elias J. Jabbour, MD, MD Anderson

February 14th 2022

Following the ASH 2021 annual meeting, expert hematologist/oncologists discuss updates in chronic lymphocytic leukemia.

ASH 2021: Key Data in Chronic Myeloid Leukemia

ByMatthew S. Davids, MD, MMSc, Dana-Farber Cancer Institute,Jae Park, MD, Memorial Sloan Kettering Cancer Center,Elias J. Jabbour, MD, MD Anderson

February 7th 2022

Shared insight on updates in the chronic myeloid leukemia treatment landscape following the ASH 2021 annual meeting.

ASH 2021: Novel Therapy in Acute Lymphocytic Leukemia

ByMatthew S. Davids, MD, MMSc, Dana-Farber Cancer Institute,Jae Park, MD, Memorial Sloan Kettering Cancer Center,Elias J. Jabbour, MD, MD Anderson

January 31st 2022

Expert perspectives on clinical data readouts in acute lymphocytic leukemia from the ASH 2021 annual meeting.

ASH Updates for CAR T-Cell Therapy in Acute Lymphoblastic Leukemia

ByRichard M. Stone, MD, Dana-Farber Cancer Institute,Ryan D. Cassaday, MD, University of Washington/Fred Hutch,Jae Park, MD, Memorial Sloan Kettering Cancer Center,Bijal Shah, MD, Moffit Cancer Center

March 4th 2021

Evolving Field of Acute Lymphoblastic Leukemia

ByRichard M. Stone, MD, Dana-Farber Cancer Institute,Ryan D. Cassaday, MD, University of Washington/Fred Hutch,Jae Park, MD, Memorial Sloan Kettering Cancer Center,Bijal Shah, MD, Moffit Cancer Center

March 4th 2021

Investigational CAR T-Cell Therapy in Acute Lymphoblastic Leukemia

ByRichard M. Stone, MD, Dana-Farber Cancer Institute,Ryan D. Cassaday, MD, University of Washington/Fred Hutch,Jae Park, MD, Memorial Sloan Kettering Cancer Center,Bijal Shah, MD, Moffit Cancer Center

February 25th 2021

CAR T-Cell Therapy Use in Second Line Acute Lymphoblastic Leukemia

ByRichard M. Stone, MD, Dana-Farber Cancer Institute,Ryan D. Cassaday, MD, University of Washington/Fred Hutch,Jae Park, MD, Memorial Sloan Kettering Cancer Center,Bijal Shah, MD, Moffit Cancer Center

February 25th 2021

CAR T-Cell Therapy After First Relapse of Acute Lymphoblastic Leukemia

ByRichard M. Stone, MD, Dana-Farber Cancer Institute,Ryan D. Cassaday, MD, University of Washington/Fred Hutch,Jae Park, MD, Memorial Sloan Kettering Cancer Center,Bijal Shah, MD, Moffit Cancer Center

February 18th 2021

Approach to Managing Relapsed Acute Lymphoblastic Leukemia

ByRichard M. Stone, MD, Dana-Farber Cancer Institute,Ryan D. Cassaday, MD, University of Washington/Fred Hutch,Jae Park, MD, Memorial Sloan Kettering Cancer Center,Bijal Shah, MD, Moffit Cancer Center

February 18th 2021

Role of Transplant in Older Adults With Acute Lymphoblastic Leukemia

ByRichard M. Stone, MD, Dana-Farber Cancer Institute,Ryan D. Cassaday, MD, University of Washington/Fred Hutch,Jae Park, MD, Memorial Sloan Kettering Cancer Center,Bijal Shah, MD, Moffit Cancer Center

February 11th 2021

Managing MRD-Negative Acute Lymphoblastic Leukemia

ByRichard M. Stone, MD, Dana-Farber Cancer Institute,Ryan D. Cassaday, MD, University of Washington/Fred Hutch,Jae Park, MD, Memorial Sloan Kettering Cancer Center,Bijal Shah, MD, Moffit Cancer Center

February 11th 2021

Managing MRD-Positive Acute Lymphoblastic Leukemia

ByRichard M. Stone, MD, Dana-Farber Cancer Institute,Ryan D. Cassaday, MD, University of Washington/Fred Hutch,Jae Park, MD, Memorial Sloan Kettering Cancer Center,Bijal Shah, MD, Moffit Cancer Center

February 4th 2021

Treatment of Acute Lymphoblastic Leukemia in the Community Setting

ByRichard M. Stone, MD, Dana-Farber Cancer Institute,Ryan D. Cassaday, MD, University of Washington/Fred Hutch,Jae Park, MD, Memorial Sloan Kettering Cancer Center,Bijal Shah, MD, Moffit Cancer Center

February 4th 2021

Role of MRD Testing in Acute Lymphoblastic Leukemia

ByRichard M. Stone, MD, Dana-Farber Cancer Institute,Ryan D. Cassaday, MD, University of Washington/Fred Hutch,Jae Park, MD, Memorial Sloan Kettering Cancer Center,Bijal Shah, MD, Moffit Cancer Center

January 28th 2021

Treating Older Adult Patients With Philadelphia Chromosome-Negative ALL

ByRichard M. Stone, MD, Dana-Farber Cancer Institute,Ryan D. Cassaday, MD, University of Washington/Fred Hutch,Jae Park, MD, Memorial Sloan Kettering Cancer Center,Bijal Shah, MD, Moffit Cancer Center

January 28th 2021

Treating Young Adult Patients With Philadelphia Chromosome-Negative ALL

ByRichard M. Stone, MD, Dana-Farber Cancer Institute,Ryan D. Cassaday, MD, University of Washington/Fred Hutch,Jae Park, MD, Memorial Sloan Kettering Cancer Center,Bijal Shah, MD, Moffit Cancer Center

January 21st 2021

Treating Older Adult Patients With Philadelphia Chromosome-Positive ALL

ByRichard M. Stone, MD, Dana-Farber Cancer Institute,Ryan D. Cassaday, MD, University of Washington/Fred Hutch,Jae Park, MD, Memorial Sloan Kettering Cancer Center,Bijal Shah, MD, Moffit Cancer Center

January 13th 2021

Treating Young Adult Patients With Philadelphia Chromosome–Positive ALL

ByRichard M. Stone, MD, Dana-Farber Cancer Institute,Ryan D. Cassaday, MD, University of Washington/Fred Hutch,Jae Park, MD, Memorial Sloan Kettering Cancer Center,Bijal Shah, MD, Moffit Cancer Center

January 13th 2021

Prognostic Factors Which Impact ALL Management

ByRichard M. Stone, MD, Dana-Farber Cancer Institute,Ryan D. Cassaday, MD, University of Washington/Fred Hutch,Jae Park, MD, Memorial Sloan Kettering Cancer Center,Bijal Shah, MD, Moffit Cancer Center

January 13th 2021

Advice for Community Oncologists on Treating HCL

BySteven Coutre, MD, Stanford University Medical Center,Farhad Ravandi-Kashani, MD, MD Anderson Cancer Center,Jae Park, MD, Memorial Sloan Kettering Cancer Center,Alan Saven, MD, Scripps Health,Andrea Sitlinger, MD, Duke University Cancer Institute

June 30th 2020

Treatments for Relapsed/Refractory HCL in Pipeline

BySteven Coutre, MD, Stanford University Medical Center,Farhad Ravandi-Kashani, MD, MD Anderson Cancer Center,Jae Park, MD, Memorial Sloan Kettering Cancer Center,Alan Saven, MD, Scripps Health,Andrea Sitlinger, MD, Duke University Cancer Institute

June 30th 2020

The Role of CD22-targeted Immunotoxins in HCL

BySteven Coutre, MD, Stanford University Medical Center,Farhad Ravandi-Kashani, MD, MD Anderson Cancer Center,Jae Park, MD, Memorial Sloan Kettering Cancer Center,Alan Saven, MD, Scripps Health,Andrea Sitlinger, MD, Duke University Cancer Institute

June 30th 2020

Landscape Change in the Treatment of Relapsed/Refractory HCL

BySteven Coutre, MD, Stanford University Medical Center,Farhad Ravandi-Kashani, MD, MD Anderson Cancer Center,Jae Park, MD, Memorial Sloan Kettering Cancer Center,Alan Saven, MD, Scripps Health,Andrea Sitlinger, MD, Duke University Cancer Institute

June 30th 2020

Historical Treatment for Relapsed/Refractory HCL

BySteven Coutre, MD, Stanford University Medical Center,Farhad Ravandi-Kashani, MD, MD Anderson Cancer Center,Jae Park, MD, Memorial Sloan Kettering Cancer Center,Alan Saven, MD, Scripps Health,Andrea Sitlinger, MD, Duke University Cancer Institute

June 30th 2020

When to Not Use Combination and the Need for Bone Marrow Biopsy in HCL

BySteven Coutre, MD, Stanford University Medical Center,Farhad Ravandi-Kashani, MD, MD Anderson Cancer Center,Jae Park, MD, Memorial Sloan Kettering Cancer Center,Alan Saven, MD, Scripps Health,Andrea Sitlinger, MD, Duke University Cancer Institute

June 30th 2020

Combination First-line Therapy in Hairy Cell Leukemia

BySteven Coutre, MD, Stanford University Medical Center,Farhad Ravandi-Kashani, MD, MD Anderson Cancer Center,Jae Park, MD, Memorial Sloan Kettering Cancer Center,Alan Saven, MD, Scripps Health,Andrea Sitlinger, MD, Duke University Cancer Institute

June 30th 2020

Determining When to Treat and First-Line Therapy for HCL

BySteven Coutre, MD, Stanford University Medical Center,Farhad Ravandi-Kashani, MD, MD Anderson Cancer Center,Jae Park, MD, Memorial Sloan Kettering Cancer Center,Alan Saven, MD, Scripps Health,Andrea Sitlinger, MD, Duke University Cancer Institute

June 30th 2020

Differential Diagnosis and Molecular Tests in Identifying HCL

BySteven Coutre, MD, Stanford University Medical Center,Farhad Ravandi-Kashani, MD, MD Anderson Cancer Center,Jae Park, MD, Memorial Sloan Kettering Cancer Center,Alan Saven, MD, Scripps Health,Andrea Sitlinger, MD, Duke University Cancer Institute

June 30th 2020

Signs and Tests for Diagnosis and Prognosis of HCL

BySteven Coutre, MD, Stanford University Medical Center,Farhad Ravandi-Kashani, MD, MD Anderson Cancer Center,Jae Park, MD, Memorial Sloan Kettering Cancer Center,Alan Saven, MD, Scripps Health,Andrea Sitlinger, MD, Duke University Cancer Institute

June 30th 2020

Molecular Genetic Changes for Hairy Cell Leukemia

BySteven Coutre, MD, Stanford University Medical Center,Farhad Ravandi-Kashani, MD, MD Anderson Cancer Center,Jae Park, MD, Memorial Sloan Kettering Cancer Center,Alan Saven, MD, Scripps Health,Andrea Sitlinger, MD, Duke University Cancer Institute

June 30th 2020

Articles by Jae Park, MD, Memorial Sloan Kettering Cancer Center

ASH 2021: Updates in the Chronic Lymphocytic Leukemia Treatment Landscape

ASH 2021: Key Data in Chronic Myeloid Leukemia

ASH 2021: Novel Therapy in Acute Lymphocytic Leukemia

ASH Updates for CAR T-Cell Therapy in Acute Lymphoblastic Leukemia

Evolving Field of Acute Lymphoblastic Leukemia

Investigational CAR T-Cell Therapy in Acute Lymphoblastic Leukemia

CAR T-Cell Therapy Use in Second Line Acute Lymphoblastic Leukemia

CAR T-Cell Therapy After First Relapse of Acute Lymphoblastic Leukemia

Approach to Managing Relapsed Acute Lymphoblastic Leukemia

Role of Transplant in Older Adults With Acute Lymphoblastic Leukemia

Managing MRD-Negative Acute Lymphoblastic Leukemia

Managing MRD-Positive Acute Lymphoblastic Leukemia

Treatment of Acute Lymphoblastic Leukemia in the Community Setting

Role of MRD Testing in Acute Lymphoblastic Leukemia

Treating Older Adult Patients With Philadelphia Chromosome-Negative ALL

Treating Young Adult Patients With Philadelphia Chromosome-Negative ALL

Treating Older Adult Patients With Philadelphia Chromosome-Positive ALL

Treating Young Adult Patients With Philadelphia Chromosome–Positive ALL

Prognostic Factors Which Impact ALL Management

Advice for Community Oncologists on Treating HCL

Treatments for Relapsed/Refractory HCL in Pipeline

The Role of CD22-targeted Immunotoxins in HCL

Landscape Change in the Treatment of Relapsed/Refractory HCL

Historical Treatment for Relapsed/Refractory HCL

When to Not Use Combination and the Need for Bone Marrow Biopsy in HCL

Combination First-line Therapy in Hairy Cell Leukemia

Determining When to Treat and First-Line Therapy for HCL

Differential Diagnosis and Molecular Tests in Identifying HCL

Signs and Tests for Diagnosis and Prognosis of HCL

Molecular Genetic Changes for Hairy Cell Leukemia

Latest Updated Articles

Trending on OncLive

FDA Approves Daratumumab and Hyaluronidase Plus VRd for Newly Diagnosed Multiple Myeloma

PD-L1 Expression Is More Predictive of Response to Pembrolizumab on Metastatic Sites in High-Grade Serous Ovarian Cancer

Ixazomib-Containing Combinations Signal Potential for More PI-Based Regimens in R/R Multiple Myeloma

Dr Braunstein on the FDA Approval of Subcutaneous Daratumumab With VRd For Newly Diagnosed Multiple Myeloma

Meta-Analysis Characterizes Nivolumab/Ipilimumab Hyperprogression in Renal Medullary Carcinoma